Biovail Exits U.S. Primary Care Market; Narrows Focus To Specialty Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
In an attempt to boost profitability, Biovail will divest its Teveten franchise to Kos, which will also gain distribution rights for Cardizem LA. The $104 mil. deal also includes an R&D collaboration for three products in Biovail's cardiovascular product pipeline.